HTB

Side effects

Dolutegravir linked to less sleep but not cardiovascular or other CNS side effects, or IRIS

Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?

Increased frequency and progression of kidney disease in HIV positive people

Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

High rates of of undocumented efavirenz-related side effects in Uganda

Case report of capsulitis with elvitegravir and cobicistat (EVG/c)

Further reports of CNS-related side effects with dolutegravir

Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring

Bone loss with PrEP in MSM aged 18-24

Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice

Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART

Efavirenz associated with suicide risk in analysis from START study

Persistent HPV infection may be related to tissue type in HIV positive people

Alcohol risks are higher in HIV positive people and linked to increased mortality

Renal monitoring in HIV positive patients: a new review

No difference in neuropsychological test results between early and delayed ART in START substudy

Immediate ART in START linked to greater bone loss over three years

Doubled hypogonadism rate in middle-aged men with HIV: fat is a factor

Neurocognitive disorder, persistent inverted CD4:CD8 ratios and immune activation in the CNS

CMV associated with 50% increased risk of non-AIDS related mortality in HIV positive people

Impact of smoking on life expectancy in HIV infection

Suicide not associated with efavirenz use in the D:A:D cohort study

Gender differences in use of cardiovascular disease-related interventions: D:A:D study

Efavirenz decreases exposure to hormonal contraceptive implant

Increased risk of ART-related hepatotoxicity in HIV positive pregnant women

Efavirenz-associated gynaecomastia reported to the national HIV and TB healthcare workers hotline in South Africa

Poppers-related maculopathy linked to permanent and serious vision loss

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Rosuvastatin may be partially effective in moderating residual immune activation on ART

Kidney signal trouble worsens over 5 years in Japanese on tenofovir

Bone mineral density linked to inflammatory markers in HIV positive people who are ART naïve

No increase death rate in HIV positive people with renal dysfunction receiving tenofovir in Zambia

Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

Efavirenz is associated with higher suicide risk in meta-analysis of four ACTG studies

Longitudinal changes in weight, lean body mass and bone mineral density in first-line combinations: ACTG 5205 substudy

ARVs and bone health: the role of NRTIs in second-line therapy

Ending global use of d4T: UNITAID to tip market to safer alternatives

Osteonecrosis in HIV positive patients is associated with increased levels of CRP and D-dimer

No impact of ART on progression or regression of anal squamous intraepithelial lesions

Incidence of cancers in Australian observational cohort

Statin use in HIV positive people

No impact of ART on progression or regression of anal squamous intraepithelial lesions

Osteonecrosis in HIV positive patients is associated with increased levels of CRP and D-dimer

Cognitive disorders are common in French cohort but are not HIV-related

Smoking is largest contributor to reduced life expectancy in Danish HIV cohort

Low bone mineral density in MSM irrespective of HIV status

Low incidence of liver-related deaths in HIV positive people without HBV and/or HCV co-infection

Rapid drop in mitochondria in fat biopsies within four weeks of d4T use

High dose multivitamin use in advanced HIV has no benefit to CD4 and viral load and may cause liver toxicity

Increased incidence of ischemic stroke amongst HIV positive cohort

First report: atazanavir-related gallstones (cholelithiasis)

High prevalence of peripheral neuropathy in children taking d4T in rural South Africa

Skeletal muscle toxicity and raltegravir

Proteinuria as a potential early marker of tenofovir-related renal toxicity

Earlier and greater comorbidities reported in HIV positive cohort

Theratechnologies withdraw EU application for tesamorelin (Egrifta)

Recent studies on HIV, ART and osteoporotic fracture risk

One third of HIV positive people at five UK clinics have symptomatic depression: link to adherence and viral suppression – 40% cases are untreated

Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations

Outcomes from switches to atazanavir/r in London

20% people switch Atripla due to efavirenz side effects: late switches are common

Risk factors associated with End Stage Renal Disease (ESRD) in HIV positive patients in the US Veterans Association (VA) cohort

Associations between tenofovir use and renal complications in VA cohort

No association between atazanavir and MI or stroke in D:A:D study

Post navigation